What factors impact your choice of first line therapy for PDL1-negative metastatic TNBC?

The first-line treatment landscape for PD-L1-negative metastatic TNBC has been transformed by ASCENT-03 and TROPION-Breast02. ASCENT-03 showed improved median PFS with sacituzumab govitecan compared with chemotherapy, while TROPION-Breast02 showed improved PFS with datopotamab deruxtecan and also de...

For patients with advanced triple-negative breast cancer (TNBC) with a PD-L1 combined positive score (CPS) less than 10, first-line treatment options include the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG), as supported by ASCENT-03 [1], or datopotamab deruxtecan (Dato-DXd), as suppor...

We are fortunate to have two ADCs that have proven superiority to chemotherapy in the first-line setting for patients who are not candidates for checkpoint inhibitors. Both DatoDxd and SG are category 1 preferred options according to NCCN for this setting and are favored over chemotherapy. Aside fro...

We are fortunate that we have two ADC choices. I think these decisions are made based on (1) familiarity with ADC and its AEs; (2) the AE profile; and (3) dosing interval. I think the efficacy of both SG and Dato-DXd is roughly equivalent. It is likely to involve preferences of the patient and the p...